Estrogen-based hormone replacement therapy (HRT) prescribing has more than doubled over the past eight years, driven by changing medical guidance, celebrity advocacy, and a major regulatory shift that removed longstanding safety warnings. The surge has created unprecedented demand for estrogen patches, leading to widespread shortages that industry experts warn could last up to three years .

Why Are Estrogen Patches Suddenly in Such High Demand?

The dramatic increase in HRT use reflects a fundamental shift in how the medical community and the public view hormone therapy. For two decades following the 2002 Women's Health Initiative study, HRT use plummeted due to concerns about cardiovascular risks and cancer. However, subsequent research has challenged those findings, showing that risks vary significantly based on age, timing of therapy initiation, and hormone formulation .

The turning point came in July 2025, when the FDA convened an expert panel to reassess HRT safety. On November 10, 2025, the agency removed the black box warning, the FDA's most prominent safety alert, from certain hormone therapy products . This regulatory reversal, combined with high-profile advocacy from public figures like Oprah Winfrey and Michelle Obama, along with clinicians who have written widely read books about menopause, created a cultural shift that encouraged more women to seek treatment .

The impact was immediate. Following the FDA's November action, patch use jumped 26% through February 2026, according to health data company Truveta . Telehealth platform HRT Club reported that patch sales rose 150% since the FDA's November actions .

How Dramatically Have Prescription Rates Climbed?

The numbers tell a striking story. Estrogen-based HRT prescribing increased from 11.5 per 1,000 women in January 2018 to 23.5 per 1,000 women in February 2026, representing a 104.8% increase overall . The growth has been particularly pronounced among women aged 45 to 54, the primary demographic for menopause treatment. This age group saw a 184.2% increase in prescriptions, with 1 in 20 women in this age group having evidence of an estrogen-based HRT prescription by February 2026 .

The shift in delivery methods is equally significant. While oral HRT has declined, patches and vaginal creams have become the preferred routes of administration. Patch use more than tripled from 2018 to 2026, rising from 6.2 to 19.9 per 1,000 women, making patches the most common form of HRT administration by February 2026 . Vaginal cream use showed an even more dramatic increase, rising from 2.8 to 14.3 per 1,000 women, a 413.3% increase .

Why Can't Manufacturers Keep Up With Demand?

Despite the surge in prescriptions, estrogen patches remain generic medications with low profit margins. This creates a fundamental problem: manufacturers have little financial incentive to invest in new production lines or facilities, which can take years to build . Additionally, long-term supply contracts can hinder manufacturers from quickly adjusting to sudden demand changes .

Major manufacturers including Amneal, Zydus, Sandoz, Noven, and Viatris all have some doses in shortage, according to the American Society of Health-System Pharmacists . Sandoz, a Swiss generics manufacturer, has shipped additional supplies to the United States to help ease shortages, but the company acknowledged that the FDA's November action created "unprecedented demand that cannot fully be met at present" .

The shortage has real consequences for patients. Women are pharmacy-hopping in search of patches, reducing or switching dosages, and changing brands or types of therapy . Abruptly stopping use can restart menopause symptoms, while switching brands may bring new side effects, according to doctors .

Steps to Navigate HRT Shortages and Treatment Options

• Communicate with your doctor: If you're unable to find your prescribed patch, discuss alternative HRT formulations with your physician. Vaginal creams, vaginal inserts or rings, topical gels, and oral formulations remain available, though patches have become the preferred option for many women.
• Plan ahead for refills: Contact your pharmacy in advance to check availability before your prescription runs out. Some patients have found success planning for shortages at major chains and using online pharmacies like Cost Plus Drugs, though wait times may be longer.
• Avoid abrupt discontinuation: If you must switch formulations or brands due to shortages, work with your healthcare provider to make the transition gradually. Stopping HRT suddenly can trigger a return of hot flashes, mood swings, and sleep disturbances.

What Does the Research Show About HRT Benefits Beyond Symptom Relief?

Recent studies suggest that early HRT initiation offers benefits that extend far beyond managing hot flashes and night sweats. A large study presented at the 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons examined more than 137,000 postmenopausal women over a five-year period and found that women who initiated HRT within one year of their menopause diagnosis had significantly lower risk of developing osteoporosis . The non-HRT group demonstrated a 18% higher risk of osteoporosis compared to the HRT group . Additionally, the non-HRT group had a 13% higher risk of fracture at maximum follow-up .

"As our population ages, age-related conditions like bone loss have become common, and the risk of falling and fracturing bones increases exponentially. Anything we can do to mitigate the risk of conditions like osteoporosis and fractures for postmenopausal women is a positive step," said James Barsi, MD, Clinical Associate Professor of Orthopaedic Surgery at Stony Brook University.

James Barsi, MD, Clinical Associate Professor of Orthopaedic Surgery, Stony Brook University

Emerging research also suggests that timing matters for brain health. An analysis of 53 studies involving over 8.4 million postmenopausal participants found that women who initiated HRT within five years of menopause experienced a 32% lower risk of Alzheimer's disease . However, the same analysis found that women who started HRT at age 65 or older showed a 38% increased risk in randomized controlled trials, suggesting that the window of opportunity for HRT's protective effects may be limited .

"This menopausal transition is actually a neurological transition," remarked Roberta Brinton from the University of Arizona. "As estrogen levels diminish, the brain is compelled to find alternative mechanisms for generating energy. Emerging evidence suggests that the brain might resort to a form of self-cannibalization, utilizing essential compounds vital for its maintenance and function as an energy source."

Roberta Brinton, University of Arizona

The disparity in findings between study types underscores the importance of timing. Randomized controlled trials, which typically enrolled older women, showed increased Alzheimer's risk with HRT, while observational studies, which included younger participants, showed reduced risk . This suggests that initiating HRT near menopause onset, rather than years later, may be key to realizing protective benefits.

As the shortage persists and demand continues to climb, experts emphasize the importance of individualized treatment decisions. The American College of Obstetricians and Gynecologists advises patients using HRT to discuss with their doctor annually whether to continue therapy, weighing both benefits and risks based on personal health factors . With estrogen patches in short supply and alternative formulations available, the conversation between patients and healthcare providers has become more important than ever.

" }